Translational predictions of phase 2a first-in patient efficacy studies for antituberculosis drugs
R. M. Savic, J. J. N. Goh, J. P. Ernest, N. Strydom, Q. Wang, R. C. van Wijk, N. Zhang, A. Deitchman, E. Nuermberger
The paper predicts clinical efficacy of antituberculosis drugs using preclinical PKPD data and translational pharmacology models to reduce phase 2a trial costs and failures.
bioRxiv · Jan 18, 2023Pharmacology & Toxicology